Tomorrow at #ASCO21, don’t miss Dr. @sandrapdangelo presenting new data from our SPEARHEAD-1 Phase 2 #clinicaltrial, including 2 complete responses and an ORR of 41% in synovial #sarcoma & 25% for MRCLS. Learn more: https://t.co/Dubtn1ikFk
@bradloncar Thats because in the case of COVID plays, the market wrongly believes it's a one horse race and is not distinguishing between different treatment modalities.